- BridgeBio Pharma Inc BBIO has executed a definitive credit facility agreement with a syndicate of lenders for up to $750 million in financing.
- This facility, combined with the Company's existing cash balance of $599.6 million, provides access to over $1.2 billion to advance the Company's pipeline programs.
- The financing is expected to fully fund BridgeBio's portfolio of more than 30 drug development and discovery programs into 2024.
- Morgan Stanley & Co. LLC acted as the sole placement agent to BridgeBio on this transaction.
- Latham & Watkins LLP acted as counsel to BridgeBio.
- Related: BridgeBio Pharma's Candidate For Muscle-Wasting Disorder Wins Fast Track Tag In US.
- Price Action: BBIO shares are down 0.35% at $45.94 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
